Arch Therapeutics Provides Corporate Milestone Update, Including Anticipated Filing of 510(k) for AC5(TM)
February 16, 2017 11:05 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 16, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH), developer of innovative materials as hemostatic and wound care devices,...
Arch Therapeutics to Provide Corporate Updates at Two Conferences in New York, February 2017
February 08, 2017 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 8, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and...
Arch Therapeutics Announces Issuance of Method-of-Use Patent Covering Self-Assembling Peptidomimetics
February 02, 2017 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 2, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, announced...
Arch Therapeutics to Present at Noble Financial Capital Markets' Thirteenth Annual Equity Conference
January 23, 2017 09:44 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jan 23, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5™ devices for use in...
Arch Therapeutics to Present at The Biotech Showcase(TM) 2017 Conference on January 10th, 2017
January 05, 2017 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jan 5, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5™ devices for use in controlling...
Arch Therapeutics to Present at 9th Annual LD Micro Main Event on December 7, 2016
December 05, 2016 18:03 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Dec 5, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics Reports AC5 Topical Hemostatic Device Successfully Stopped Bleeding in Patients on Antiplatelet Therapy in Recently Completed Clinical Study
October 31, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Oct 31, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of devices for use in controlling bleeding and fluid loss in order to...
Arch Therapeutics Will Present at the 2016 Bio Investor Forum in San Francisco, California October 18-19th, 2016
October 11, 2016 08:10 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Oct 11, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics Will Present at the 2016 Aegis Capital Growth Conference in Las Vegas, NV September 20-22, 2016
September 15, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Sep 15, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics Provides Corporate Update at the 18th Annual Rodman & Renshaw Global Investment Conference
September 12, 2016 19:07 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Sep 12, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of AC5™ devices for use in controlling bleeding and fluid loss in...